|  |  |
| --- | --- |
| **SERVICE SPECIFICATION NO:** |       |
| **SERVICE:** | Liverpool Place Spacer Provision Service |
| **PROVIDER:** |  |
| **Commissioner Lead** | Geraldine McKerrell |
| **Provider Lead** |  |
| **Period** | 1st April 2025 – 31st March 2026 |
| **Date of Review** | February 2025 |

**Version Control:**

|  |  |  |  |
| --- | --- | --- | --- |
| **Version No:** | **Section Edited:** | **Editing Author:** | **Date:** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

# SCHEDULE 2 – THE SERVICES

1. **Service Specifications**

Mandatory headings 1 – 4: mandatory but detail for local determination and agreement

Optional headings 5-7: optional to use, detail for local determination and agreement.

All subheadings for local determination and agreement

|  |  |
| --- | --- |
| **Service Specification No.** |       |
| **Service** | Liverpool Place Spacer Provision Service |
| **Commissioner Lead** | Geraldine McKerrell |
| **Provider Lead** |  |
| **Period** | 1st April 2025 – 31st March 2026 |
| **Date of Review** | February 2025 |

|  |
| --- |
| **1. Population Needs** |
|  **1.1 National/local context and evidence base** This Service Specification defines the terms and standards required by the commissionersfor the provision of the Spacer Provision Service under which the commissioned Service Provider (The community pharmacy contractor) and community pharmacists can provide a spacer to patients who are using a pMDI inhaler and require a replacement. **1.2 Local context** In order to expedite the patient’s receipt of a spacer, and to save pharmacy and practice time; pharmacies will be able to supply a spacer to patients that are highlighted as requiring one, including a replacement.  |
| **2. Outcomes** |
| **2.1 NHS Outcomes Framework Domains & Indicators**

|  |  |  |
| --- | --- | --- |
| **Domain 1** | **Preventing people from dying prematurely** |  |
| **Domain 2** | **Enhancing quality of life for people with long-term conditions** | **[x]**  |
| **Domain 3** | **Helping people to recover from episodes of ill-health or following injury** |  |
| **Domain 4** | **Ensuring people have a positive experience of care** | **[x]**  |
| **Domain 5** | **Treating and caring for people in safe environment and protecting them from avoidable harm** | **[x]**  |

* 1. **Local defined outcomes**
		1. Providing timely access to spacer devices for patients that are highlighted as requiring one.
		2. Reducing demand on General Practice prescribing, by allowing Pharmacists to supply spacer devices directly to patients.
		3. Supporting the delivery of proactive care for long term respiratory conditions.
 |
| **3. Scope** |
| * 1. **Aims and objectives of service**
		1. To help patients that require a spacer device to obtain one in a timely manner.
		2. To improve efficiency and speed in supplying a spacer device to patients that require them.
		3. To improve the benefit of the pMDI inhaler to a patient.
		4. To reduce negative effects that poor inhaler technique has on long-term respiratory conditions.
	2. **Service description/care pathway**
		1. Patients that require a spacer will be identified within the pharmacy.
		2. Patients will be identified by Pharmacists conducting services such as the New Medicines Service, through any Pharmacy Quality Scheme indicators, or any other conversations or interventions with a patient whereby a pharmacist believes a spacer is needed to aid the patient’s inhaler technique.
		3. The pharmacist will discuss the use of a spacer with the patient.
		4. Pharmacists should be mindful that local and national guidance supports the use of large-volume spacer devices over low-volume spacer devices, however the spacer device to be supplied should be agreed with the patient, taking into consideration patient requirements.
		5. Volumatic Spacers are the first-line option under the Pan-Mersey formulary for large-volume spacers. For further information on devices and compatibility see RightBreathe [Ciphaler® device by Cipla EU ltd - RightBreathe](https://www.rightbreathe.com/?s=&device_type=spacer&UNLID=42919207620252171438)
		6. The patient must consent for their GP to be notified of the supply before a supply is made. Patients that refuse will not be able to receive a spacer. The GP does not need to be notified when patients receive a replacement spacer of the same kind as previously.
		7. If consulting the patient (or carer for children) face-to-face, the pharmacist should show the patient (or carer) how the spacer device works alongside their pMDI inhaler.
		8. If consulting over the phone, the patient (or carer) should be directed to the information leaflet within the spacer device on how to use the device. Alternatively, the patient (or carer) can ask to be shown on collection of the device from the pharmacy.
		9. The spacer supplied should be documented on the patient’s PMR.
		10. A record of the provision will be made on PharmOutcomes at the time of the supply, or in case of IT issues at the soonest possible moment following its restoration.
		11. A notification will be sent from PharmOutcomes on completion of the provision on the system. In case of IT issue, the pharmacy will print this and send via secure NHSmail to the GP surgery, or via post.
		12. The service provider must keep all completed electronic consultation proformas for a period of 8 years (in adults) or until 25th birthday in a child (age 26 if entry made when the young person was 17) or eight years after death in line with NHS health records retention policies.
		13. The pharmacist will determine whether the patient is exempt from paying prescription charges or not. If the patient is not exempt and is supplied a device, the pharmacist will charge the patient an amount equivalent to the prescription charge and will be reimbursed for the supply fee/NHSBSA Drug Tariff price of device issued *less* the prescription charge.
	3. **Pharmacist Training and Development**
		1. Pharmacists who deliver this service must have completed the [CPPE inhaler technique for health professionals: getting it right training](https://www.cppe.ac.uk/programmes/l/inhalers-e-02) and passed the [e-assessment](https://www.cppe.ac.uk/programmes/l?t=Inhalers-A-08&evid=);
		2. The responsible pharmacist on each given day has overall responsibility for ensuring the service is delivered in accordance with this service specification.
	4. **Equality and Diversity**

The service provider must comply with the requirements of the Equality Act 2010 and will not treat one group of people less favorably than others because of age, disability, gender reassignment, marriage or civil partnership, race, religion or belief, sex or sexual orientation. |
| **4. Applicable Service Standards** |
| **4.1 Applicable national standards (e.g. NICE)**4.1.1 Supply of ALL devices must be in accordance with the Human Medicines Regulations 2012 and within the medication’s product license.4.1.2 All devices supplied under the service must be labelled to comply with the Human Medicines Regulations 2012. 4.1.3Devices supplied under the Spacer Provision Service must be supplied with a patient information leaflet. 4.1.4 Records created during the delivery of the Spacer Provision Service should be managed according to the NHS Code of Practice. **4.2 Applicable standards set out in Guidance and/or issued by a competent body (eg Royal Colleges)** The Spacer Provision Service may only be provided by Pharmacists with a current registration with the General Pharmaceutical Council from premises that hold a current contract to supply NHS Pharmaceutical Services. **4.3 Applicable local standards**It is expected that the service will be offered consistently throughout the opening hours of the branch including evenings, weekends and Bank Holidays. |
| **6. Location of Provider Premises** |
| **The Provider’s premises are located at:**See Schedule 2A of the NHS Standard Contract |